BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.610
+0.010 (0.63%)
Mar 30, 2026, 1:55 PM EDT - Market open
BeyondSpring Employees
BeyondSpring had 40 employees as of December 31, 2024. The number of employees increased by 4 or 11.11% compared to the previous year.
Employees
40
Change (1Y)
4
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$14,950
Market Cap
66.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 40 | 4 | 11.11% |
| Dec 31, 2023 | 36 | -37 | -50.68% |
| Dec 31, 2022 | 73 | -30 | -29.13% |
| Dec 31, 2021 | 103 | 12 | 13.19% |
| Dec 31, 2020 | 91 | 30 | 49.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Fractyl Health | 101 |
| XBiotech | 85 |
| InflaRx | 74 |
| PMV Pharmaceuticals | 54 |
| Cognition Therapeutics | 28 |
| Gain Therapeutics | 25 |
| Dogwood Therapeutics | 8 |
BYSI News
- 4 days ago - BeyondSpring Files 2025 Annual Report on Form 10-K - GlobeNewsWire
- 7 weeks ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 3 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 7 months ago - BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) - Seeking Alpha
- 9 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 10 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 11 months ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire